|Bid||3.0300 x 1800|
|Ask||3.0400 x 1200|
|Day's Range||3.0000 - 3.1500|
|52 Week Range||2.8100 - 7.0200|
|Beta (5Y Monthly)||2.72|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 31, 2021 - Jun 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for the first quarter 2021 and business update on Friday, May 14, 2021. The Company's management will host a conference call to discuss the financial results and provide a business update on recent corporate and clinical developments at 8:30 a.m. Eastern Daylight Time (EDT).
John Vandermosten, CFA NYSE:PLX Following the anticipated April 27 th target action date for its investigational candidate, Protalix Biotherapeutics, Inc. (NYSE:PLX) announced that the FDA had issued a Complete Response Letter (CRL) related to the submission of PRX-102. 1 Protalix and Chiesi Global Rare Disease submitted the Biologics License Application (BLA) for the PEGylated enzyme and
NEW YORK, NY / ACCESSWIRE / April 28, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Protalix BioTherapeutics, Inc. ("Protalix" or "the Company") (NYSE:PLX).